ABSTRACT
Aim: The manuscript describes the performance of nanoparticles loaded with antidepressant drug for nose-to-brain drug delivery. Materials & methods: Poly-lactic-co-glycolic acid-loaded nanoparticles of agomelatine were prepared by nanoprecipitation method using poloxamer 407 as stabilizer. The process parameters were optimized using factorial design. Results: The drug-loaded nanoparticles having low particle size (<200 nm) with narrow size distribution and required zeta potential (-22.7 mV) to avoid aggregation showed sustained release profile and were found to have higher permeability as observed from ex vivo studies when compared with plain drug suspension. Histopathology test showed that the optimized formulation was free from nasal toxicity on the goat nasal mucosa. Pharmacodynamic study showed significant reduction in immobility time in rats treated with the formulation which indicated antidepressant activity of the formulation. Conclusion: The prepared agomelatin-loaded poly-lactic-co-glycolic acid nanoparticles showed prominent antidepressant activity by nose-to-brain delivery as observed from various studies.
Subject(s)
Acetamides/administration & dosage , Antidepressive Agents/administration & dosage , Depression/drug therapy , Drug Carriers/chemistry , Nanoparticles/chemistry , Acetamides/pharmacokinetics , Acetamides/toxicity , Administration, Intranasal , Animals , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/toxicity , Behavior Observation Techniques , Behavior, Animal/drug effects , Blood-Brain Barrier/metabolism , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Depression/diagnosis , Depression/etiology , Disease Models, Animal , Drug Carriers/toxicity , Drug Compounding/methods , Goats , Humans , Nanoparticles/toxicity , Nasal Mucosa/drug effects , Nasal Mucosa/metabolism , Polylactic Acid-Polyglycolic Acid Copolymer/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer/toxicity , Rats , Toxicity TestsABSTRACT
The aim of the current investigation was to develop solid lipid nanoparticles of olmesartan medoxomil using hot homogenization method to improve its oral bioavailability. Central composite design was applied to optimize the formulation variables; lipid X1 (Glyceryl monostearate) and surfactant X2 (Poloxamer: Tween 80). The particle sizes were in the nanometer range and spherical shaped for all prepared solid lipid nanoparticles formulations and the zeta potential absolute values were high, predicting good long-term stability. In vitro study of olmesartan loaded solid lipid nanoparticle exhibited controlled release profile for at least 24â¯h. The rate and extent of drug diffusion was studied using dialysis sac, rat's stomach and intestine tissues; study demonstrated that drug release from the solid lipid nanoparticles was significantly higher than drug suspension. In vivo pharmacokinetic study of olmesartan loaded solid lipid nanoparticles revealed higher Cmax of 1610â¯ng/mL, higher AUC of 15492.50â¯ng/mL and increased relative bioavailability by almost 2.3 folds compared to marketed formulation. These results clearly indicate that olmesartan loaded solid lipid nanoparticles are shown to have enhanced bioavailability and effective therapeutic result and thus would be an excellent way to treat hypertension. Hence, these solid lipid nanoparticles could represent as a great potential for a possible alternative to conventional oral formulation in the treatment of hypertension.
Subject(s)
Drug Delivery Systems , Hypertension/drug therapy , Lipids/chemistry , Nanoparticles/chemistry , Olmesartan Medoxomil/administration & dosage , Olmesartan Medoxomil/therapeutic use , Administration, Oral , Animals , Diffusion , Drug Compounding , Drug Liberation , Freeze Drying , Gastric Mucosa/metabolism , Intestinal Mucosa/metabolism , Male , Nanoparticles/ultrastructure , Olmesartan Medoxomil/pharmacokinetics , Particle Size , Rats, Wistar , Static ElectricityABSTRACT
The aim of the presented study was to develop PEGylated liposomes of Temozolomide (TMZ) that provide optimum drug concentration at tumor site. Reverse phase evaporation (REV) method was used to prepare TMZ-loaded PEGylated liposomes. Formulation was optimized by using design expert software by 32 factorial design. The physicochemical properties including size, morphology, entrapment efficiency, drug loading, etc. of formulated liposomes were evaluated. Finally, the optimized formulation was selected for in vitro drug release and stability study. In vivo pharmacokinetic study in rats showed that TMZ-loaded PEGylated liposomes leads to 1.6-fold increase in AUCTotal in blood and 4.2-fold increase in brain as compared to free drug solution. This formulated PEGylated liposomes offers a promising approach for treatment of Glioblastoma Multiforme.